The GELATO clinical trial was a lobular breast-cancer specific immunotherapy trial investigating the response to an immunotherapy + chemotherapy medication combination. This phase 2 trial was open to metastatic lobular breast cancer patients and was conducted in the Netherlands. This trial has been discontinued.
Name of the trial: GELATO (AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer). NCT03147040
Goal of this Trial: This clinical trial (recruiting patients as of August 2018) aimed to discover if a combination of chemotherapy and an immunotherapy medication is effective in lobular breast cancer patients. Additionally, this trial looked to discover if there are any markers that correlate with response to this combination of medications.
Background: There are recent studies indicating that tumors in a subset of patients with lobular breast cancer express many immune cell markers, and/or are infiltrated by immune cells, and thus might be responsive to therapies targeting the immune system (Ciriello et al, PMID:26451490; Michaut et al, PMID:26729235; Desmedt et. al, PMID:29471435; Du, et. al, PMID: 29739984).
Clinical Trial location: The trial took place in the Netherlands (locations in Amsterdam, Groningen, Maastricht, Rotterdam.)
Eligible patients: Patients with metastatic lobular breast cancer who are residents of the Netherlands were eligible for the study. The trial coordinator had considered others who can speak Dutch and have a place to stay during the early part of the trial.
Leonie Voorwerk, MD, The Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses the GELATO trial in an interview that was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
For more information regarding the clinical trial, please contact the Principal Investigator Marleen Kok, MD at +3120512 ext 9111 or firstname.lastname@example.org and review the trial listing on the ClinicalTrials.gov website.
The Lobular Breast Cancer Alliance shares information about ongoing clinical for lobular breast cancer. LBCA does not sponsor or run the clinical trials, and the scientific validity and safety of the trials is the responsibility of the trial investigators. Learn more by contacting the clinical trial coordinators listed above directly.
Patients should always discuss their participation in any clinical trial directly with their doctor – these Questions to Ask your Doctor may help. Learn more about participating in clinical trials. Learn about other lobular breast cancer clinical trials and studies.